Oral mucositis.
Chemotherapy
mucositis
radiotherapy
traditional medicine
Journal
National journal of maxillofacial surgery
ISSN: 0975-5950
Titre abrégé: Natl J Maxillofac Surg
Pays: India
ID NLM: 101578767
Informations de publication
Date de publication:
Historique:
received:
31
01
2020
revised:
21
06
2020
accepted:
13
07
2020
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
27
4
2021
Statut:
ppublish
Résumé
Oral mucositis is one of the most common complications of cancer therapy. It is a nonhematologic complication of cytotoxic chemotherapy and radiotherapy and reduces the quality of life. It is estimated that 40% the cases on standard chemotherapy may develop oral mucositis. Patients receiving radiation, especially in the cases of head and neck cancer, have 30%-60% chances of developing mucositis. Chemotherapy and radiotherapy interfere with the normal turnover of epithelial cells, leading to mucosal injuries. These injuries can also occur due to indirect invasion of Gram negative bacteria and fungi as most of the chemo-therapeutic agents will cause neutropenia and will give a favorable environment for the development of mucositis. The patient-related factors are also responsible for developing mucositis in chemo-induced and radiation-induced mucositis. Poor oral hygiene may also be responsible for bacterial super infection followed by chemotherapy. Mucositis is of two kinds: direct and indirect mucositis. Direct mucositis - The epithelial cells of the oral mucosa undergo rapid turnover in usually 7-14 days due to which these cells are more susceptible to the effect of the cytotoxic therapy which results in oral mucositis. Indirect mucositis - it can develop due to the infection caused by Gram-negative bacteria and fungal infection. There will be a greater risk for oral infection due to neutropenia. The onset of mucositis secondary to mylo-suppression varies depending upon the timing of the neutrophil count associated with chemotherapy agents but they typically develop around 10-21 days after chemotherapy administration.
Identifiants
pubmed: 33897175
doi: 10.4103/njms.NJMS_10_20
pii: NJMS-11-159
pmc: PMC8051654
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
159-168Informations de copyright
Copyright: © 2020 National Journal of Maxillofacial Surgery.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Support Care Cancer. 2013 Nov;21(11):3233-41
pubmed: 23842598
Integr Cancer Ther. 2016 Mar;15(1):60-8
pubmed: 26306626
Support Care Cancer. 2019 Oct;27(10):3997-4010
pubmed: 31286229
Support Care Cancer. 2019 Oct;27(10):4023-4033
pubmed: 31286231
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
Oral Oncol. 2009 Dec;45(12):1015-20
pubmed: 19828360
Neoplasia. 2004 Sep-Oct;6(5):423-31
pubmed: 15548350
Eur J Oncol Nurs. 2005;9 Suppl 1:S24-32
pubmed: 16202654
Arch Oral Biol. 2019 Sep;105:20-26
pubmed: 31238198
Support Care Cancer. 2013 Nov;21(11):3209-21
pubmed: 23764678
Oral Oncol. 2010 Jun;46(6):452-6
pubmed: 20403721
Radiother Oncol. 2016 Jul;120(1):13-20
pubmed: 27113797
Evid Based Complement Alternat Med. 2013;2013:284959
pubmed: 24285975
Transl Oncol. 2018 Jun;11(3):771-778
pubmed: 29698934
Eur J Oncol Nurs. 2015 Apr;19(2):136-41
pubmed: 25465773